On January 21, 2020 Seattle Genetics, Inc. (Nasdaq:SGEN) reported that it will receive a milestone payment from Roche triggered by European Commission conditional marketing authorisation for Polivy (polatuzumab vedotin). Polivy is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics’ technology (Press release, Seattle Genetics, JAN 21, 2020, View Source [SID1234553371]). It was developed and is commercialized by Roche/Genentech. Polivy was approved in combination with bendamustine plus MabThera (rituximab) (BR) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a haematopoietic stem cell transplant. Polivy was granted PRIME (PRIority MEdicines) designation by the European Medicines Agency (EMA) for the treatment of people with R/R DLBCL in 2017.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"In addition to our two marketed ADC products ADCETRIS (brentuximab vedotin) and the recently FDA-approved PADCEV (enfortumab vedotin-ejfv), the European Commission approval of Polivy highlights the increasing importance of ADCs in the treatment of cancer," said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "Across our internal and collaborator pipelines, there are more than ten ADCs in clinical development employing our proprietary technology. We continue to lead in the field of ADCs with our novel linker systems, cell-killing payloads and conjugation technologies."
Seattle Genetics’ ADC technology combines the specificity of monoclonal antibodies, innovative linker systems and potent cell-killing agents to treat cancer. The technology has been licensed to several companies, including Roche/Genentech and GlaxoSmithKline. Under the terms of these agreements, each licensee company has rights to use the technology with antibodies against specified targets. The licensee is responsible for research, product development, manufacturing and commercialization. Seattle Genetics is entitled to receive fees, progress-dependent milestone payments and royalties on worldwide net sales of any resulting ADC products.